• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600530.SS
Share

Shanghai Jiaoda Onlly Co.,Ltd Stocks

CN¥ 4Last Updated 22.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 431.60M

CN¥ 4
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Jiaoda Onlly Co., Ltd., together with its various subsidiaries, primarily operates within China's health food sector. The company's product portfolio is extensive, featuring functional health items, probiotics, traditional tonics, dietary supplements, and natural extracts, alongside a range of disinfection solutions. Beyond health-related products, the firm is also engaged in the wholesale and retail distribution of pharmaceutical goods, as well as the production and sale of other food products. Further diversifying its operations, Shanghai Jiaoda Onlly provides road cargo and transportation services, in addition to offering travel agency activities. Headquartered in Shanghai, China, this company was founded in 1990.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 02:52

Anthropic has released a new, cost-effective AI model. How did the creator of ChatGPT respond?

23.09.2026 01:36

The Nasdaq closed at a record high for the second day in a row. Oil prices fell to a two-week low.

23.09.2026 00:34

Meta Has Created a "Killer Product": What Wall Street Is Saying About the New AI Assistant, Muse

22.09.2026 23:28

Trump at the UN: The U.S. Must Either Reach an Agreement on Iran's Nuclear Program or "Send Them to Hell"

22.09.2026 22:47

"Bad Guys" Had Their Accounts Closed: Standard Chartered Responds to Article on Sanctions Evasion

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026